Anti-proliferative effects induced by anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody

Abstract

The effects of chimeric anti-CD4 human/murine chimeric antibody and murine anti-CD4 monoclonal antibody (McAb) on the proliferation induced by anti-CD3 McAb, phytohemagglutinin (PHA), IL-2, and allogeneic cells were studied. The results showed that chimeric anti-CD4 antibody and murine anti-CD4 McAb could inhibit the proliferation induced by the above inducers and the inhibitory effects were related to the dosage of the antibodies.

Keywords

CD4 molecule / chimeric antibody / monoclonal antibody / inhibition of proliferation

References

[1] GreensteinJ L, BurakoffS J. The role of L3T4 (CD4) in T cell activation. Ann Inst Pasteur Immunol, 1987, 138: 134-134

[2] EichmannK, BoyceN W, Schmidt-UllrichR. Distinct functions of CD8(CD4) are utilized at different sites of T lymphocyt-differentiation. Immunol Rev, 1989, 109: 39-39

[3] ShenG, ZhuZ, ZhuH, et al. . Expression of anti-CD4 human/murine chimeric antibody and their killer tumor activity. J Tongji Med Univ, 1998, 18: 1-1

[4] MoussionC, TanterY E. CD4 and CD25 monoclonal antibody cocktail in kedney transplant rejection prophylaxis: clinical results of a pilotstudy. Transplantation Proc, 1995, 27: 1727-1727

[5] RobinetE, FournelS, FatmiA, et al. . IL-2 resistant hyporesponsiveness induced by CD4 mAbs in OKT3-activated human T cells is reversed by CD45RA triggerring. Cellular immunol, 1996, 167: 1-1

[6] QinS, CobboldS P, TigheH, et al. . CD4 monoclonal antibody pairs for immunosuppression and tolerence induction. Eur J Immunol, 1987, 17: 1159-1159

[7] AdoriniL, GueryJ C, Rodringurz-TarduchyG, et al. . Selective immunosuppression. Immunology Today, 1993, 14: 285-285

[8] MorelP, VincetC, WijdensJ, et al. . Down-regulation of cell surface CD4 molecule expression induced by anti-CD4 antibody in human T lymphocytes. Cellular Immunol, 1991, 145: 287-287

[9] WeissenhornW, ScheuerW, KaluzaB, et al. . Combinatorial functions of two chimeric antibodies directed to human CD4 and one directed to the α-chain of the human interleukin-2 receptor. Gene, 1992, 127: 271-271

[10] MorelandL W, PrattP W, BucyR P, et al. . Treatment of refractory rheumatoid arthritis with a chimeric anti-CD4 monoclonal antibody: Long-term follow-up of CD4⁺ cells counts. Arthritis Rheum, 1994, 37: 834-834

[11] JonkerM, SlingerlandW, TreacyG, et al. . In vivo treatment with a monoclonal chimeric anti-CD4 antibody results in prolonged depletion of circulating CD4⁺ cells in chimpanzees. Clin Exp Immunol, 1993, 93: 301-301

[12] AndersonA, ChambersK, HannaN, et al. . A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4⁺ T cells in chimpanzees;in vitro and vivo characterization of a MAb (IDEC-CE9. 1) to human CD4. J Immunol, 1997, 84: 73-73

[13] HerzogC H, WalkerC D, MullerW. Anti-CD4 antibody treatment of patients with rheumatoid arthritis. I. Effect on clinical couse and circulating T cells. J Autoimmun, 1989, 2: 627-627